Within 1 year, centers in every state in Australia were performing 68Ga-PSMA PET/CT and in less than 4 years, this form of targeted molecular imaging is not only being incorporated into routine clinical management of prostate cancer patients serviced by 40 centers country-wide, but arguably has become the standard of care throughout Australia in the diagnosis, selective staging and monitoring of therapeutic response of prostate cancer. Here, FOLH1 is linked to Familial prostate cancer.